Advanced Cell Technology

Losses at Advanced Cell Technology (ACT) of Marlborough deepened in its first quarter, as the cost of clinical trials for its macular degeneration treatments rose, the company said.

Advanced Cell Technology of Marlborough nearly doubled its fourth-quarter revenue to end 2012, but reported a net loss of $10.3 million, the biotech firm reported Thursday.

Marlborough-based Advanced Cell Technology Inc. said its clinical partner, the University of California – Los Angeles (UCLA), has received U.S. Food and Drug Administration approval to perform clinical trials using ACT's retinal pigment epithelial (RPC) cells, which are derived from human embryonic stem cells, to treat nearsightedness.

Advanced Cell Technology (ACT) of Marlborough said it has reached a settlement agreement in a lawsuit it faced over the conversion of debt notes and the exercise price of certain warrants.

After Marlborough-based Advanced Cell Technology's shareholders approved a reverse stock split this summer, the company said today it will not complete the split because of "market conditions and other corporate factors."

As the country continues to shake off the effects of the recession that hit in 2007, MetroWest's...

Marlborough-based Advanced Cell Technology (ACT) has finished treating three more patients in its two U.S. clinical trials...

Advanced Cell Technology Inc., a Marlborough based regenerative medicine company, reported losses in revenue and net income...

Marlborough-based Advanced Cell Technology announced that it has made a $35-million deal with an investor that will...

Marlborough-based Advanced Cell Technology (ACT), which is developing stem cell treatments for eye diseases, praised a recent...